Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Xvivo Perfusion ABXVIPF 86 3-Year FCF Growth Rate is -11.30% as of Jun. 2026. GuruFocus rates XVIPF with a GF Score™ of 86/100 and a GF Value™ of $43.46 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 587 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks worse than 78.36% on this metric.
During the past 12 months, Xvivo Perfusion AB's average Free Cash Flow per Share Growth Rate was 202.00% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -11.30% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was -4.60% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was -33.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Xvivo Perfusion AB was 19.30% per year. The lowest was -79.60% per year. And the median was -20.00% per year.
Xvivo Perfusion AB (OTCPK:XVIPF) 3-Year FCF Growth Rate Explanation
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Xvivo Perfusion AB 3-Year FCF Growth Rate Related Terms
XVIPF vs ABT, SYK, MDT: 3-Year FCF Growth Rate Comparison
For the Medical Devices subindustry, Xvivo Perfusion AB's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB 3-Year FCF Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's 3-Year FCF Growth Rate falls into.
Xvivo Perfusion AB 3-Year FCF Growth Rate Calculation
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of -11.30% mean?
Xvivo Perfusion AB (XVIPF) has a 3-Year FCF Growth Rate of -11.30% as of Jun. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Xvivo Perfusion AB and its competitors. According to the industry distribution chart, Xvivo Perfusion AB ranks #460 out of 587 companies in the Medical Devices & Instruments industry, placing it in the top 78.4%.
Is Xvivo Perfusion AB's 3-Year FCF Growth Rate too high?
Xvivo Perfusion AB's current 3-Year FCF Growth Rate is -11.30%. Based on the distribution chart, Xvivo Perfusion AB ranks #460 out of 587 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Xvivo Perfusion AB has a GF Score™ of 86/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's 3-Year FCF Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #460 out of 587 companies for 3-Year FCF Growth Rate. This places Xvivo Perfusion AB in the lower half of its industry. The industry median 3-Year FCF Growth Rate is 17.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Medical Devices & Instruments company?
The median 3-Year FCF Growth Rate among Medical Devices & Instruments companies is 17.90, based on 587 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year FCF Growth Rate is 17.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current 3-Year FCF Growth Rate is -11.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $43.46, compared to a current price of $26.07 — trading 40% below its estimated fair value. The current 3-Year FCF Growth Rate is -11.30%. Xvivo Perfusion AB's overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current 3-Year FCF Growth Rate is -11.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $26.07 is trading 40% below its estimated GF Value™ of $43.46.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
3-Year FCF Growth Rate: -11.30%
GF Value™: $43.46 vs. price of $26.07 (40% below fair value)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
86GF Score
Get the complete analysis for XVIPF
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 
